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Abstract
Background & Aims—The inflammatory bowel diseases (IBD) ulcerative colitis (UC) and 
Crohn’s disease (CD) cause significant morbidity and are increasing in prevalence among all 
populations, including African Americans. More than 200 susceptibility loci have been identified 
in populations of predominantly European ancestry, but few loci have been associated with IBD in 
other ethnicities.
Methods—We performed 2 high-density, genome-wide scans comprising 2345 cases of African 
Americans with IBD (1646 with CD, 583 with UC, and 116 inflammatory bowel disease 
unclassified [IBD-U]) and 5002 individuals without IBD (controls, identified from the Health 
Retirement Study and Kaiser Permanente database). Single-nucleotide polymorphisms (SNPs) 
associated at P<5.0×10−8 in meta-analysis with a nominal evidence (P<.05) in each scan were 
considered to have genome-wide significance.
Results—We detected SNPs at HLA-DRB1, and African-specific SNPs at ZNF649 and LSAMP, 
with associations of genome-wide significance for UC. We detected SNPs at USP25 with 
associations of genome-wide significance associations for IBD. No associations of genome-wide 
significance were detected for CD. In addition, 9 genes previously associated with IBD contained 
SNPs with significant evidence for replication (P<1.6×10−6): ADCY3, CXCR6, HLA-DRB1 to 
HLA-DQA1 (genome-wide significance on conditioning), IL12B, PTGER4, and TNC for IBD; 
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IL23R, PTGER4, and SNX20 (in strong linkage disequilibrium with NOD2) for CD; and KCNQ2 
(near TNFRSF6B) for UC. Several of these genes, such as TNC (near TNFSF15), CXCR6, and 
genes associated with IBD at the HLA locus, contained SNPs with unique association patterns 
with African-specific alleles.
Conclusions—We performed a genome-wide association study of African Americans with IBD 
and identified loci associated with CD and UC in only this population; we also replicated loci 
identified in European populations. The detection of variants associated with IBD risk in only 
people of African descent demonstrates the importance of studying the genetics of IBD and other 
complex diseases in populations beyond those of European ancestry.
Keywords
SNP; genetic analysis; Risk factor; Trans-Ethnic
Inflammatory bowel disease (IBD), a chronic intestinal inflammatory disorder, affects over 
1.4 million people in the US alone and is a significant burden on resources with healthcare 
costs estimated at greater than $6 billion/year1. Historically a disease of the developed world 
and European ancestry populations, recent years have seen a rising prevalence in non-
European populations including African-Americans (AAs). Association studies have 
previously identified 200 genome-wide significant (GWS) IBD susceptibility loci in 
European ancestry populations2, 3. At least thirty-five loci have been identified in Asians and 
a handful appear Asian specific3–7.
We recently performed the first large-scale evaluation of established IBD genetic loci in the 
understudied African American (AA) population, using the Immunochip genotyping 
platform (Illumina San Diego, CA), in 1,511 cases and 1,797 controls4. We found significant 
replication in AAs for maximal established SNPs at 5 European loci for IBD and CD 
(FCGR2A and PTGER4 for IBD; IL23R, NOD2, and IKZF3 for CD) and for UC at HLA 
rs9271366, congruent with the maximal East Asian HLA association. We also observed 
strong association signals at PTGER4, IL12B, and STAT3A/STAT5 for SNPs independent of 
established European association signals. African-specific IBD risk SNPs (i.e. SNPs present 
only in African populations or in populations with African ancestry, and monomorphic or 
unknown in other 1000 genome populations) were detected for STAT3A/STAT5. No loci, 
however, had SNPs with evidence of GWS association nor were any African-specific loci 
established, although we found suggestive evidence (p<4×10−5 with consideration for the 
relatively small number of SNPs evaluated) for 3 potential novel loci (i.e. C2orf43, 
HDAC11, and LINC00994)4.
It is hoped that genetic advances will enable more personalized approaches to managing 
IBD. Given that significant differences in pathological and molecular mechanisms may exist 
in AAs, who have a higher risk for developing disease complications in IBD and worse 
disease outcome, it is imperative to use more comprehensive genotyping platforms in more 
highly powered samples to detect population specific IBD loci and associations. 8–11. We 
hypothesized that high-density GWAS of IBD in AAs could identify population specific 
variants, further define IBD genetic architecture, and expose novel disease mechanisms.
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MATERIALS AND METHODS
Study design
We conducted two GWAS using independent case-control datasets, totaling 2345 AA IBD 
cases (1646 CD, 583 UC and 116 IBD-U) and 5002 controls population (Figure 1) from 
unrelated, self-identified AAs individuals. Samples with IBD from GWAS1 (n=1258 IBD 
cases [843 CD, 368 UC, 47 IBD-U]) were recruited by Johns Hopkins Multicenter African 
American IBD Study (MAAIS) (coordinated by Johns Hopkins IBD Genetics Research 
Center [GRC] of the NIDDK IBD Genetics Consortium [IBDGC] with recruitment from 13 
collaborating IBD centers and 4 other IBDGC GRCs12) and at Cedars-Sinai Medical Center 
IBD Center. Control AA subjects of GWAS1 (n=1678) were derived from the dbGaP Health 
and Retirement Study (HRS), a longitudinal panel study sponsored by the National Institute 
on Aging. Samples with IBD from GWAS2 (n=1087 IBD cases [803 CD, 215 UC, 69 IBD-
U]) were obtained by Emory University from the GENESIS study (an ancillary study of the 
NIDDK IBDGC, coordinated by Emory University with recruitment of IBD cases and 
matched controls from 12 of their collaborating IBD centers and the RISK study, a large 
pediatric CD inception cohort with recruitment of IBD cases from 29 IBD centers13). The 
GWAS2 AA control subjects (n=3324) were obtained from the Kaiser RPGEH study (a 
research program at Kaiser Permanente in California with the goal of discovering which 
genes and environmental factors linked to specific diseases).
Genotyping, Quality Control (QC) and Population Ancestry
All DNA samples for GWAS1 were genotyped on the Illumina Omni 2.5 (~2.3 million 
SNPs) or Omni 2.5 Exome (~2.6 million SNPs) arrays according to the manufacturer’s 
protocol. The two channel raw data files (.idat) for all samples were transferred to a central 
location and assembled into a single project for joint genotype calling. Samples for GWAS2 
were genotyped on the Affymetrix Axiom Genome-Wide AFR 1 World Array 3 (African 
array) (Affymetrix, Inc., Santa Clara, California) according to the manufacturer’s protocol. 
The World Array 3 contains ~894,000 SNPs optimized for individuals of African ancestry.
For each GWAS, samples with low call rates (<97.5%) were excluded. SNPs that failed the 
HWE test (p<0.00001) in the controls were removed. We tested for agreement between X/Y 
genotypes and sex, and for unexpected relatedness between individuals by applying 
RELPAIR and GRR14 to 10,000 – 20,000 markers in linkage equilibrium (Pairwise r2<0.1) 
evenly distributed across the genome. Samples with discordant gender were excluded from 
analyses. For pairs of individuals that appeared to be genetically related, one of the pair was 
removed from subsequent analyses. One member from all first and second degree relative 
pairs (r >= 0.25) was dropped. To investigate population structure and identify population 
group outliers, we used principal components analysis (PCA). Beginning with all SNPs that 
passed QC, we first filtered down to a small (~20,000) subset of SNPs with moderate minor 
allele frequency and no linkage disequilibrium (LD) (r2<0.1). We inferred principal 
components (PCs) for all samples of each phase cohort using the method proposed by Price 
et al15 as implemented in the software package EIGENSTRAT. Samples were plotted in PC 
space, and outliers that exceeded thresholds of <−0.05 or >0.05 for both PC1 or PC2 were 
rejected (Supplementary figure 1). In all, we excluded 121 samples in GWAS1 and 126 
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samples in GWAS2. The genomic control values for CD, UC and IBD were 1.04, 1.02 and 
1.03 in the GWAS1 analysis, and 1.04, 1.01 and 1.04 in the GWAS2 analysis, respectively, 
indicating little evidence of population stratification after controlling for global ancestries 
and suggesting that there was no inflation of false positives from confounding by ancestry. 
PCs were included as covariates in our downstream analyses.
Imputation-based association analysis, meta-analysis and conditional analysis
Before imputation, an initial quality control was performed separately on each set of case-
control datasets using Plink16. The initial step included filtering out SNPs with genotyping 
call rate <0.99, Hardy-Weinberg equilibrium p<1×10−5, and minor allele frequency <0.01. 
Additionally, a filter that excluded all A/T or G/C SNPs was applied. To improve the 
coverage of genetic variants, the datasets were separately imputed to the 1000 Genomes 
Project Phase 3 integrated autosomal reference panel, using the software IMPUTE217. 
GWAS1 included 2.47 million genotyped SNPs imputed to 11.9 million SNPs and GWAS2 
included 893,815 SNPs imputed to 11.5 million SNPs. After excluding SNPs with low 
imputation quality, indels and copy number variants (CNVs), imputed genotypes were 
combined with the observed sample genotype data set for association analysis. Genotype 
imputation clouds (i.e. the full genotype probability values, not single point estimates) from 
IMPUTE2 were directly used to assess association with SNPTEST (version 2.5.2 or a 
later)18 under an additive model (-frequentist 1, -method score parameter options). Ten PCs 
were included in all SNPTEST analyses. For each GWAS, association analyses were 
performed separately for UC, CD and IBD (CD and UC combined). Association P-values of 
<5×10−8 (corresponding to a genome-wide significance level of 0.05 after a Bonferroni 
correction for multiple testing of 1M SNPs) were considered statistically significant. A total 
of ~11.9 million and ~11.5 million markers were analyzed from the Illumina Omni 2.5 and 
Axiom arrays, respectively.
To combine data between the cohorts of GWAS1 and GWAS2, all results were meta-
analyzed with the program METAL (versions 1.7 or later)19, using an inverse-variance, 
fixed-effects model, after controlling for residual test statistic inflation via genomic control. 
SNPs with minor allele frequency less than 0.01 or imputation quality scores less than 0.5 
were excluded. Following exclusions, 11.4 milion SNPs were available for meta-analysis. 
The meta-analysis was well powered to identify common variants with OR ≥ 1.3. Owing to 
numerous single SNP associations within the extended linkage disequilibrium (LD) of HLA 
region (Supplementary figure 2A), we performed an exploratory analysis conditioned on 
SNP rs9270299 (a non-synonymous coding variant [c.179A>G, p.Ala29Thr]) to narrow 
associations to those with the best evidence for strength and independence. The conditional 
association analysis was performed using SNPTEST 2.5.218. SNPs were annotated using 
annovar20.
Validation of ZNF649 genotypes
The 6 SNPs most highly associated within the ZNF649 locus were in perfect LD with each 
other (r2~1). SNP rs75075099 and rs75577191 were genotyped by Taqman assay in 96 
randomly selected samples. Genomic DNA of the 96 randomly selected AAs with UC was 
quantitated via UV absorbance using Nanodrop 1000 (Thermo Scientific, Wilmington, DE, 
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USA) and 10 nanogram of DNA was used for allelic discrimination using TaqMan SNP 
genotyping assay (assay IDs C__27836655_10 and C__25965275_10, Applied Biosystems, 
Foster City, CA, USA). Genotypes were determined automatically using the ABI Prism 
7900HT SDS software suite (SDS version 2.4, Applied Biosystems, Foster City, CA, USA). 
We compared the genotype probability from the imputation to the genotyped observed by 
the Taqman assay. Genotypes for 85 and for 9 DNAs from the 96 randomly selected AAs 
were high confidence homozygote reference and heterozygotes, respectively, and these were 
all confirmed by Taqman genotyping for both SNPs. The remaining 2 samples were only 
20–30% confidence heterozygotes. One was confirmed by Taqman genotyping.
Significance
Significant genome-wide association was defined using the accepted standard of p≤5×10−8, 
a Bonferroni corrected association of p≤0.05, corrected for 1 million independent tests with 
the additional requirement of nominal association (p≤0.05) in each genotyping array. Given 
that we had two independent GWAS and genotyped datasets, we set an additional criterion 
of GWS association with internal replication to define a more rigorous meta-analysis 
association evidence than that observed in a single GWAS. This was developed as follows: 
the meta-analysis of the two GWASs incorporated 11.4 million observed and imputed 
markers present across both studies. With ~11 million SNPs analyzed in each GWAS, for a 
most conservative criterion (by not taking into account LD among SNPs), we would expect 
approximately 715 unassociated SNPs to achieve p<6.5×10−5 by chance. In a replication 
study of 715 SNPs, Bonferroni multitest corrected significance would correspond to 
p<7×10−5. Thus, setting a threshold of p<6.5×10−5 in both GWAS is comparable to taking 
forward SNPs with p<6.5×10−5 from a discovery study, and then demanding Bonferroni 
corrected significance for the carried forth SNPs in a replication study. Therefore, we 
defined GWS association with internal replication as SNPs achieving GWS of p≤5×10−8 in 
the meta-analysis and p≤6.5×10−5 in each individual GWAS.
Significant evidence for locus replication within 250 kb of known loci was defined as 
p≤1.5×10−6 as follows: Given 200 established IBD loci, there will be 100,000kb of genome 
incorporated within 250 kb of each association peak (500kb combined on each side). Given 
the estimated size of the autosomal genome at 2.9 million kb, 3.4% of the genome would be 
encompassed within 250 kb of all 200 loci. Taking 1 million independent SNPs as that being 
the standard for multiple test correction for (autosomal) GWS of 0.05, approximately 34,000 
independent SNPs would be present amongst these 200 loci by chance, and association at a 
p-value of 0.05 would hence be corrected to 1.5×10−6 for any SNPs that are detected in these 
regions for IBD. Association corrected for all 11.4 million imputed SNPs at 0.05 
significance would be 1.3×10−7, but this may be considered overly conservative given that 
the majority of SNPs are not independent (for example the 6 ZNF649 GWS SNPs as noted, 
were in perfect LD).
RESULTS
The top associations per locus for UC, CD and IBD are listed in Table 1. From the meta-
analysis of UC, 5 SNPs on chromosome 19 and 41 SNPs in the HLA region achieved GWS 
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with internal replication (Figure 2A and Supplementary Table 1). The chromosome 19 SNPs 
map to the transcriptional repressor ZNF649 (Supplementary figure 3) and overlap ZNF649 
antisense RNA1 (ZNF649-AS1). A second novel GWS association was detected at African-
specific variant rs72947885 in the axonal neuronal adhesion molecule gene LSAMP 
(Supplementary Figure 2B) in UC (meta p=4.5×10−9) but did not meet criteria for internal 
replication. In fact, SNP rs72947885 was genotyped on the Axiom array (see cluster plot in 
Supplementary figure 4) but not on the Omni array, its imputation quality score suggests 
high confidence (0.976 in the Omni dataset and 0.975 in the Axiom dataset) and the 
concordance rate between the genotyped and imputed data is 0.984. Both the ZNF649 and 
LSAMP SNPs are specific to Africans (i.e. present only in African populations or in 
populations with African ancestry, and monomorphic or unknown in other populations) as 
noted by the 1000 Genomes Project Phase3 population allele frequencies (Table 1). A side-
by-side comparison of Q-Q plots with and without the HLA variants demonstrated that 
results follow the null expectation. The early upward departure of the observed values was 
being driven by the HLA signal in UC (Figure 2A and Supplementary Figure 2B). The top 
associations per locus for UC, CD and IBD are listed in Table 1.
The 3 strongest UC associations are located within the HLA-DRB1 gene. We conditioned 
association in UC, CD and IBD on the second strongest association, a non-synonymous 
coding variant (rs9270299, c.179A>G, p.Ala29Thr), in an exploratory analysis to detect 
potential independent HLA signals (Table 2). Conditioning on rs9270299 in IBD revealed 9 
SNPs with GWS for this phenotype located between BTNL2 and HLA-DQA1 (Table 2 and 
Figure 3), 6 of which are African specific (Table 2). Conditioning in CD and UC did not 
reveal additional significant associations.
Meta-analysis of CD did not detect any GWS associations (Figure 2B). In IBD, meta-
analysis detected two GWS SNPs (s73782531 located near ZNF608 and rs7278277 located 
near ubiquitin protease USP25, meta p= 8.6×10−9 and p=2.0×10−8, respectively [Figure 2C]. 
However, for ZNF608 association evidence only came from GWAS1 (p=1.6×10−16 with 
case and control allele frequencies 0.013 and 0.056, respectively) with no evidence from 
GWAS2 (p=0.63, and respective allele frequencies 0.043 and 0.44). Hence, for IBD, outside 
of the HLA signal observed on conditional analysis, only USP25 (Supplementary Figure 2C) 
met our minimal criteria of at least nominal evidence in both GWAS cohorts, and the 
ZNF608 association is more likely a false signal.
We detected numerous additional SNPs with significant locus replication (i.e. p<1.6×10−6 
within 250 kb of maximal evidence of an established locus) at established European loci 
(Table 1) within or proximal to genes ADCY3, CXCR6, HLA-DRB1 to HLA-DQA2 
(including rs139282044, GWS on conditioning), IL12B, PTGER4, and TNC for IBD; 
IL23R, PTGER4, and SNX20 (18kb from NOD2 and in LD with NOD2 R702W) for CD; 
and KCNQ2 (near TNFRSF6B) for UC. Several of these loci contained African specific 
variants (Table 1).
SNPs with strong evidence of association but below that of locus replication were also 
detected for multiple additional loci. In CD, African-specific SNPs were observed at 
rs6854424 (OR=1.85, p=5.86×10−6) 31Kb centromeric of TBCK, a gene involved with 
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regulation of mTOR signaling. In contrast, multiple universal SNPs (i.e. polymorphic in all 
populations) maximal at rs141365838 (OR 1.67, p=3.90×10−6), were observed in UC at 
NFKBIZ, an inducible regulator of NF-kB, important for TH17 cell development.2 
Interestingly, NFKBIZ was only recently identified as a UC gene via trans-ethnic meta-
analysis in Europeans, East Asians, North Indians and Iranians; our association evidence 
was stronger than that reported for each of these separate study populations (p=9.34×10−6)3. 
Other locus associations of note included CCR6 for IBD and CD, and NOTCH2 and 
CCDC69 for IBD. We again observed African specific IBD associations at STAT3, but not 
as strong in the meta-analysis (i.e. rs12721583 GWAS2 p=5.0×10−6, meta p=8.2×10−5) as in 
our previous report4. All associations with p-values < 6.5×10−5 in either GWAS are shown 
in Supplementary Table 1.
Among the SNPs reported in the updated European and trans-ethnic immunochip study3 we 
genotyped or successfully imputed 221 of 231 SNPs. Of these, 104 showed evidence of 
replication (p<0.05). ORs (direction and magnitude) observed in Europeans were excellent 
predictors for CD, UC and IBD in AA (Figure 4, A, B and C respectively). The full 
summary statistics of our analysis can be found using the following link: https://
www.dropbox.com/sh/s653tyw3yxo4mcc/AADxhOZCvb9VCOn45vvsTic0a?dl=0
DISCUSSION
In this first AA GWAS for IBD, we provide the first GWS evidence for AA IBD loci: we 
identified two novel and African specific GWS UC loci, and elevate our prior UC HLA 
association in the region of the DRB1 gene to certainty with GWS evidence. We provide 
GWS HLA association for IBD unrelated to the UC association and driven mostly by 
African specific polymorphisms; and establish the USP25 locus as GWS in AAs. We also 
found increased association evidence in AAs for NOD2 (via SNX20), IL23R and PTGER4 
loci, above that from our prior, smaller sized immunochip study, and significant locus 
replication for 4 other loci, ADCY3, CXCR6, TNC, and KCNQ2 – the majority within or 
adjacent (e.g. KCNQ2) to immune regulatory genes.
ZNF649 acts as a transcriptional repressor and its overexpression suppresses transcriptional 
activities of the Serum Response Element (SRE) and the Activating protein-1 (AP-1) 
complex21. AP-1 upregulates pro-inflammatory responses, including TNF-α in IBD22. 
Among the 5 imputed GWS with internal replication on chromosome 19, 4 SNPs 
(rs78090981, rs116142355, rs149246580, and rs116148256) map within introns of ZNF649, 
while 1 (rs75075099) maps downstream of ZNF649 at 19q13.41 (Table 1 and Supplemental 
figure 3). All 5 SNPs, which are in perfect LD (r2~1), also map within ZNF649 antisense 
RNA1 (ZNF649-AS1) and are specific to Africans (i.e. present in African populations or in 
populations with African ancestry and monomorphic or unknown in other populations) and 
mostly found in Sub-Saharan Africa. The top ranked variant, rs78090981, resides in an 
intron that is retained in one transcript of the gene (ENST00000599671), and in addition, 
may alter a regulatory motif for basic leucine zipper ATF-like transcription factor (BATF). 
The SNP rs75075099 also potentially alters some transcription factor binding sites for 
Pou5f1, TCF11 and p30023, and is associated with a number of histone marks and DNase I 
hypersensitivity in a range of cell lines24. Also, as the antisense-RNA gene for ZNF649 
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overlaps with the ZNF649 gene itself, this is another possible mechanism for regulation. All 
of these pieces of evidence suggest that ZNF649 or its antisense might be causal genes for 
this novel susceptibility locus, and targeting ZNF649 may be a potential therapeutic 
approach.
LSAMP has been characterized as an axonal neuronal adhesion molecule. Its protein product 
is also expressed in colon and platelets. Interestingly, LSAMP somatic deletions were 
associated with prostate cancer specifically in AAs25. The top ranked variant, rs72947885, is 
located in the 3’UTR and also overlaps with several transcriptional regulator motifs and is 
also reported by Ensembl to be in an enhancer region (ENSR00001988698) in some cell 
lines including B cells and M1 macrophages from venous blood. However, this variant did 
not meet the threshold for GWS with internal replication and did not have additional 
regional variants with strong evidence for association (no variants in strong LD were testable 
in the meta-analysis) and therefore more evidence from additional studies is required to 
validate this locus and LSAMP as a candidate gene.
We also showed evidence for independent GWS associations in the HLA region for UC and 
IBD, as has been shown in other populations. The 3 most highly associated variants, 
including a non-synonymous coding variant (rs9270299), were located at HLA-DRB1, a 
gene previously associated with UC. These 3 SNPs are common to all major populations 
(Table 1) and they are in LD with the previously reported top UC association in our AA 
Immunochip study, rs92713664. However, SNP rs9271366 (also found as most highly 
associated in Asian UC) did not pass our QC. To determine if there is initial evidence for 
independent HLA signals in AA IBD, we conditioned association on the rs9270299 non-
synonymous variant, and we detected multiple independent GWS SNP associations (Table 
2) in the HLA region, the majority of which are African specific, for IBD. Given the great 
allelic and LD complexity of the HLA region, our conditional analysis is considered 
exploratory and far more in-depth analyses will be necessary to better define the independent 
associations in this region for IBD in AAs. Of note, the top IBD non-conditioned analysis 
HLA signal (rs139282044, p=9.4×10−8) is represented by the same African specific variant 
revealed in the conditional analysis. Conditioning on rs9270299 also revealed a separate 
signal at rs144540865, an uncharacterized rare variant (i.e. observed or found at frequencies 
<0.5% in non-African population) that resides in BTNL2, a gene associated with IBD in 
Caucasians26 and with CD in Koreans27 by deep sequencing only. BTNL2 is expressed in 
mice in the duodenum, ileum, cecum ascending and descending colon28. BTNL2 resides 
between the MHC class II and class III regions, but is class II associated and appears to 
regulate T-cell activation. These analyses support parallel observations in Europeans that 
multiple HLA alleles contribute independently to IBD29.
USP25 is a ubiquitously expressed gene and has been established as an IBD locus in 
Europeans and shown to be associated with CD in Koreans2, 7. The SNP rs7278277 was not 
internal to this gene but is in very high LD (r2>0.8) with a number of variants that correlate 
with a multitude of regulatory regions, including promotors, enhancers and transcription 
factor binding sites. Two of these SNPs, rs7278277 and rs2242830, showed suggestive 
evidence of association in GWAS2 for CD and IBD.
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We also find evidence for multiple other IBD, CD and UC loci, several driven by African 
specific polymorphisms and some, like TNC, with unique location relative to those found in 
other populations. TNC codes for an extracellular matrix glycoprotein involved in epithelial 
cell migration, intestinal barrier function, arresting T-cell activation and is a marker of IBD 
activity30. It is located 100kb telomeric to TNFSF8 and 200kb telomeric to TNFSF15, the 
dominant CD locus in Asians and a significant locus for both CD and UC in Europeans31. 
The association patterns of diverse populations, as highlighted by the TNFSF15-TNC 
region, may allow for the fine dissection of the mechanisms of molecular genetic risk for all 
populations.
Owing to the smaller size of our AA cohort compared to the European cohorts used in 
previous studies2, 3, we had limited power to assess the extent of allele sharing between the 
two populations. However, we found evidence that disease variants for nearly half of 
European IBD loci have at least nominal evidence for an influence on IBD in AAs. This 
finding supports shared pathogenic mechanisms across different ethnicities.
One seemingly surprising finding is that we were able to identify 3 novel GWS loci for UC, 
whereas in the three-fold larger CD cases, no GWS loci were identified. Reasons include the 
dominance of HLA for UC, high risk (OR 3.41) of ZNF649 for UC with no comparable 
higher OR, single risk variants for CD, and potentially greater allelic and phenotypic 
heterogeneity underlying CD in AAs. We did however demonstrate significant locus 
replication for 6 IBD loci, 3 CD loci but only 1 UC loci. We are not aware of any evidence 
that AA UC is more genetic than CD (i.e. having a greater family history).
In summary, this first GWAS of AA IBD has demonstrated unique, African specific loci, as 
well as loci that are shared across multiple populations. While some of these shared loci 
contain unique association patterns and African specific risk variants, many contain 
universal risk variants (like HLA-DRB1) or risk variants that have arisen from European 
admixture (like NOD2). Given our results and the evolution of IBD genetics research in non-
European populations, it is clear that further studies with larger sample sizes in the AA 
population are needed to identify additional population specific variants and novel loci, as 
well as more fully characterize the role of risk variants established in other populations on 
the development of IBD in AAs. Such research is paramount to allow for the future benefits 
of IBD genetics research, from risk prediction and family counseling to targeted therapies 
and eventually disease preventive strategies to be available for the understudied AA 
population.
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Figure 1. 
Experiment design flowchart. Two independent GWAS were performed and included 1258 
cases/1678 controls (GWAS 1 genotyped on Illumina Omni2.5) and 1087 cases/3324 
controls (GWAS 2 genotyped on Affymetrix Axiom Genome-Wide AFR 1 Array). After 
quality control and imputation based association analysis of CD, UC and IBD for each 
GWAS, a combined meta-analysis of observed and imputed SNPs identified 6 SNPs above 
genome threshold that are associated with UC in African Americans.
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Figure 2. 
Figure 2A, 2B and 2C. Meta-analysis Manhattan plots for UC (2A), CD (2A) and IBD 
phenotypes, respectively. All SNPs are plotted according to their position on each 
chromosome on x-axis, against their association on y-axis. The red and blue lines indicate 
the genome-wide significance (p≤5×10−8) and the suggestive significance threshold (p ≤ 
1×10−5), respectively. Genome-wide significant signals are labeled with corresponding gene 
names. The inset QQ plots shows the observed (y-axis) against the expected (x-axis) 
distribution of p-values under the null hypothesis with and without MHC.
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Figure 3. 
LocusZoom plots of SNPs by chromosome position against –log10 p-value for their genetic 
associations with IBD phenotype. Conditional regional plot for the HLA locus (chr6p21) for 
the IBD phenotype shows SNPs reaching genome-wide significance conditioned on SNP 
rs9270299 from UC analysis. The top SNP is highlighted in purple. The surrounding SNPs, 
shown within 500kb of the top SNP are color-coded to reflect their linkage disequilibrium in 
r2 with the top SNP (see inset). Estimated recombination rates are plotted in pale blue to 
reflect local LD structure on secondary y-axis.
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Figure 4. 
Figure 4(A–C): Odds ratios of SNPs maximally associated in Caucasians versus AAs for CD 
(4A), UC (4B) and IBD (4C) phenotypes. Red line: best-fitting least-squares regression line.
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